Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →2,182 patent families on microarray gene expression hybridization platforms, with filer concentration and a decade-long filing trend.
8,367 published records collapse into 2,182 simple (DOCDB) families; the difference is the same invention filed in more than one country. INCYTE CORP is named on 101 of the 2,182 patent families in scope. One patent family can name several filers, so these figures are not slices of a divided whole and do not add up. In force = 1,398 of 8,367 records still granted and maintained at the data cut-off; the rest are pending, withdrawn, refused or lapsed.
This landscape covers records matching microarray terms together with gene expression or transcript terms, and hybridization or probe terms, in the title, abstract or claims. The search carries no date limit, so the 2,182 simple patent families and 8,367 published records in scope span every matching filing year the database holds, not a fixed window. Families de-duplicate one invention across the countries it was filed in; records count each publication separately, so the two totals answer different questions and should not be swapped for one another.
Of the 8,367 published records, 1,398 (17%) were granted and still in force at retrieval. That figure describes legal status at a single point in time across all records returned, not a success rate for the field, and it changes as documents lapse, get granted or get withdrawn.
Counted over all 8,367 published records, including filings from before 2007; the filing-trend chart below covers only the 5,317 records from 2007 onward, so the two charts are not the same set of documents. Ordered by volume only, not by importance or claim strength. Counted in simple (DOCDB) patent families, so one invention filed in several countries counts once. Names come from Patsnap's standardised assignee field as recorded on each document; subsidiaries and group companies are not merged. The icon before each name is read from the name itself (words such as University, Institute or Ltd); the data carries no organisation-type field, so treat it as a reading aid rather than a classification. 2 rows in this table start with the same name (INCYTE CORP, INCYTE PHARMA INC). They are left as separate rows, so the largest-filer figure above is per legal entity, not per group. Rows that look related still cannot be added together: one family can name several of them. Counted one by one, those rows between them cover more than the largest single row does, so the largest single row is not necessarily the largest filer in this field. How much those rows cover together is not something this dataset can say: one family can name several of them, so their counts cannot be added. Every ranking statement on this page is per individual filer row, never per group. Filings held by named individuals rather than organisations are removed where they can be identified (19 here); that identification is not exhaustive, so an individually held filing can still appear below. Either way those filings stay inside the totals above. This table shows the top 30 of the 81 filers returned for this search; the data endpoint returns at most 100 entities, so even that 81 is not the complete set of filers. A single family can name more than one filer, so these counts overlap and do not add up to the total.
The figures below are drawn directly from the search: a filing trend counted in published records by earliest filing year, and an IPC subclass breakdown counted in simple patent families.
Published records rose from 360 in 2007 to a peak of 433 in 2011, and stood at 282 in 2021 after moving from 222 in 2018, a 27% increase over that span. Years from 2022 onward are still filling in because of publication lag and are shaded on the chart; they should not be read as a fall in filing activity.
Counted in published records by earliest filing year, not de-duplicated into families. A filing is counted in the year it was filed, but it only becomes visible after it publishes: roughly 18 months for most routes, and up to 30 months where a PCT application enters national phase. 2022 onwards are therefore still filling in and are shaded; no growth figure on this page uses them. Because this series counts documents rather than inventions, a rise can mean more inventions or the same inventions filed in more countries; this dataset cannot separate the two. This chart covers 2007-2026 (5,317 records); the 8,367 total quoted above includes earlier filings outside the window.
C12Q (measuring and testing involving enzymes or DNA) appears on 78.5% of the 2,182 families, ahead of G01N (material analysis and testing) at 35.3%, C12N (microorganisms and genetic engineering) at 27.7%, and A61K (medicinal preparations) at 21.2%. Because a family can carry several IPC classes, these shares add up to more than 100% and should be read one class at a time.
Shares are the percentage of the 2,182 patent families in scope. One patent family can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about microarray based gene expression profiling hybridization platform patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe abstract describes methods and means for producing microarray, non-microarray and clone-counting gene expression and gene expression comparison assay results that are, relative to prior art assay results, described as improved in normalization, assay accuracy, biological accuracy, quantitation, interpretability or intercomparability. It states that practicing the described methods is necessary to produce accurate gene expression and gene expression comparison assay results by these approaches.This is the first record returned under the database's default ordering, not the most cited, newest or broadest filing in the set. It is shown to illustrate what one matching record claims, not to characterize the field.
View full recordSelected as the first record the search returns under the database default order, then shown in full. It is not ranked by citations, claim breadth or commercial importance, and it is not a judgement about which filing in this space matters most.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Four figures from this search, reported with the unit each is counted in and what it does and does not establish.
INCYTE CORP is named on 101 of the 2,182 simple patent families in scope (4.6%). A separate row, INCYTE PHARMA INC, is listed independently; the two are not merged or summed here because one family can name both.
None of the 81 listed filers holds 2 or fewer simple patent families. This is a count of the listed filer rows, not a share of the dataset, and the filer rows overlap so they cannot be added into a concentration figure.
Published records in this search rose from 222 in 2018 to 282 in 2021. 2021 is the most recent year treated as complete; years from 2022 onward are still filling in because of publication lag and are not evidence of a decline.
1,398 of the 8,367 published records (17%) were granted and still in force at the 2026-10-16 retrieval date. The remainder are pending, withdrawn, refused, lapsed or not determinable, and that breakdown is not available on this page.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microarray based gene expression profiling hybridization platform patent landscape, with the prior art for and against each one.
The figures here describe what the search returned. Deeper questions about claim scope, specific filer portfolios or white space need a closer read of the underlying documents.
A family count or an abstract cannot establish what a granted claim covers. Pull the claim set for any record before drawing a freedom-to-operate conclusion.
Explore full records in Eureka →2022-onward filing counts will keep rising as more records publish. Re-check the trend periodically rather than treating the most recent years as final.
Set up monitoring in Eureka →Filer rows overlap and are not rolled up to corporate group, so any question about a specific organisation's portfolio needs to be checked row by row.
Compare filers in Eureka →This search returns 2,182 simple patent families and 8,367 published records matching microarray terms together with gene expression or transcript terms, and hybridization or probe terms. Families de-duplicate one invention across the countries it was filed in, while records count each publication separately, so the two numbers answer different questions. The search carries no date limit, so this set spans every matching filing year the database holds rather than a fixed window.
INCYTE CORP is named on 101 of the 2,182 simple patent families in scope (4.6%), the largest single filer row returned by this search. A second row, INCYTE PHARMA INC, is listed separately and is not combined with the first, since one family can name both and summing them would double-count. The listed filers are organisations only; filings held by named individuals are excluded from the filer list but remain inside the overall totals.
Published records rose from 222 in 2018 to 282 in 2021, a 27% increase, with a peak of 433 records in 2011 across the full trend back to 2007. Years from 2022 onward are still filling in because a filing only becomes visible once it publishes, which can take up to 30 months for applications entering national phase via the PCT route. Those recent years should not be read as a slowdown; they are simply incomplete at the time of retrieval.
IPC subclass C12Q, covering measuring and testing involving enzymes or DNA, appears on 78.5% of the 2,182 families, the highest share in this set. G01N (material analysis and testing) follows at 35.3%, C12N (microorganisms and genetic engineering) at 27.7%, and A61K (medicinal preparations) at 21.2%. Because a single family can carry several IPC classes, these shares add up to more than 100%, and they should be read one class at a time rather than summed.
None of the 81 listed filers holds 2 or fewer simple patent families, which points to a spread of filing activity across many organisations rather than concentration in a handful of rows. Filer rows cannot be added together to produce a combined share, because one family can name several filers and the rows overlap by an unknown amount. The largest single row, INCYTE CORP, accounts for 4.6% of the 2,182 families, which on its own does not indicate a concentrated field.
Go past this page: query the whole microarray based gene expression profiling hybridization platform patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Search. Every figure on this page comes from one Patsnap search, run once and not edited afterwards. This is the exact search string:
TAC:(microarray AND ("gene expression" OR transcript*) AND (hybridization OR probe))
Reading the field codes: TAC searches the title, abstract and claims of each record, not the full description. The search string sets no date limit, so the scope is every matching record in the database regardless of when it was filed. It is not restricted to recent years. How this string was built matters for how far the counts can be pushed. It was generated in batch from a topic list rather than hand-crafted for this page, and the result set is not manually screened. A keyword search over title, abstract and claims both over-captures (unrelated filings that happen to use the same words) and under-captures (the same invention written in different words). This page cannot measure either effect, so read every figure here as what this particular string returned, not as what exists in the field. One subclass (C12Q) carries 78.5% of the patent families, so this search returned a classification-tight set.
What is being counted. Two different units appear on this page and they are not interchangeable. The filer list and the technology split are counted in simple (DOCDB) patent families: one invention counts once however many countries it was filed in. The total, the jurisdiction split and the filing-year chart are counted in published records: the same invention counts once per publication. For this search that is 8,367 records and 2,182 families. Record counts reward filing in many jurisdictions; family counts do not. Shares are only ever taken against a denominator in the same unit, and each one names it.
Who the filers are. Names come from Patsnap's standardised assignee field, as recorded on the documents themselves. They are not rolled up to corporate group: a parent and its subsidiaries appear as separate entries, and a portfolio acquired from another company stays under the name on the document unless the assignment is reflected there. This list is meant to carry organisations, not people. Filings held by a named individual are identified by matching the assignee against the inventors on the same search, and, for names written in Chinese, Japanese or Korean characters, by the name carrying no organisational suffix; those are removed from the list (19 of them here). Neither test is exhaustive: the inventor list it matches against is itself capped, and a personal name written in Latin script with no organisational wording in it cannot be told apart from a short company name by rule. So an individually held filing can still appear in the list. Those filings stay inside every total and share on this page either way, so the listed entries can add up to less than the total. A record shown in full further down still names its assignee exactly as the patent office records it, including where that is a person: that name is how the record is identified and checked. What is left out of the ranking is people as ranked entries, not people as cited sources. The table shows the top 30 of the 81 filers returned, ordered by count alone; the data endpoint returns at most 100 entities, so even that 81 is not every filer. One patent family can name several filers and each is counted separately, so these rows are not slices of a divided whole: adding them together over-counts, and this page deliberately publishes no combined "top five" share for that reason. See every filer, individuals included
Dates. The year chart counts by earliest filing year, not publication year. A filing only becomes visible once it publishes: roughly 18 months for most routes, and up to 30 months where a PCT application enters national phase. Measured across these pages, the year four back from today still holds only about 89% of its eventual count. 2022 onwards are therefore shaded on the chart as still filling in, and the growth figure stops at 2021. The data behind this page was retrieved on 2026-10-16.
Legal status. "In force" counts documents whose legal status at retrieval was granted and maintained (1,398 of 8,367). Everything else is pending, withdrawn, refused, lapsed or not determinable, and those states are not broken out here because the underlying codes do not separate them cleanly. Legal status changes continuously and is reported per document, not per family. Get the status breakdown in Eureka
Classification. The technology split uses IPC subclasses (four characters, for example H01M). A single record usually carries several, so the shares add up to more than 100% and a record can appear in more than one bar. Subclass is a coarse grouping; it describes the field a record was classified into, not what the claims cover. Break the classes down to subgroup level
Who wrote the words. The tables, charts, counts, shares and patent numbers on this page are produced directly from the search result by a program; none of them are written or estimated by a language model. The surrounding prose, headings, FAQ answers and the answers in the question panel are drafted by a language model that is given those same figures and is not permitted to introduce others. Prose can still mis-describe a correct figure, so where the two disagree, the tables and charts are the record.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries limitations that apply to every figure above. Recent filings are under-counted, because an application is not public until roughly 18 months after filing and database loading adds further delay. The search string defines and constrains everything shown: records that use different terminology, or that sit outside the fields searched, are absent and cannot be counted. Applicant names, classification codes, legal-status codes and citation records are taken as recorded and may contain errors, duplicates, omissions or stale entries. Ordering by volume is not a measure of quality, scope, enforceability or commercial value, and a larger portfolio is not a stronger one. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, validity or infringement search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. No attorney-client relationship is created by it. Any patent, commercial, or strategic decision should be verified independently against the primary records and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
The question panel. The answers behind the suggested questions on this page were written when the page was generated, not in response to your click. The progress steps that play before an answer appears are an animation of how that analysis was done; nothing is being searched or computed at that moment. Typing your own question instead opens Patsnap Eureka, which does run it live.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page